药物对比
Canagliflozin vs Nateglinide
比较SGLT2抑制剂Canagliflozin（Invokana）与格列奈类药物Nateglinide治疗2型糖尿病，重点在于促进肾脏葡萄糖排泄与刺激胰腺胰岛素分泌的差异。
此页面暂无可用的对比维度。
临床背景
This comparison arises when choosing between an SGLT2 inhibitor and a meglitinide for type 2 diabetes based on insulin secretion needs versus glucose excretion.
结论
Canagliflozin and Nateglinide offer distinct mechanisms for type 2 diabetes control with neither universally superior.
全部药物对比